Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. BioStem Technologies's Revenue for the
three
months ended in Sep. 2025 was $10.5 Mil. BioStem Technologies's average Accounts Receivable for the
three
months ended in Sep. 2025 was $62.5 Mil.
Hence, BioStem Technologies's Receivables Turnover for the
three
months ended in Sep. 2025 was 0.17.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
BioStem Technologies Receivables Turnover Related Terms
BioStem Technologies Receivables Turnover Historical Data
* Premium members only.
The historical data trend for BioStem Technologies's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSEM vs XLO, TCRX, MNOV: Receivables Turnover Comparison
For the Biotechnology subindustry, BioStem Technologies's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioStem Technologies Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioStem Technologies's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where BioStem Technologies's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioStem Technologies (BSEM) has a Receivables Turnover of 0.17 as of Sep. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on BioStem Technologies and its competitors. According to the industry distribution chart, BioStem Technologies ranks #557 out of 841 companies in the Biotechnology industry, placing it in the top 66.2%.
Is BioStem Technologies' Receivables Turnover too high?
BioStem Technologies' current Receivables Turnover is 0.17. The Biotechnology industry median Receivables Turnover is 5.29. BioStem Technologies' value of 0.17 is 96.8% below this industry median. Based on the distribution chart, BioStem Technologies ranks #557 out of 841 companies in the Biotechnology industry, which is below the industry midpoint. Overall, BioStem Technologies has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioStem Technologies' Receivables Turnover compare to XLO and TCRX?
According to the Biotechnology industry distribution chart, BioStem Technologies ranks #557 out of 841 companies for Receivables Turnover. This places BioStem Technologies in the lower half of its industry. The industry median Receivables Turnover is 5.29. BioStem Technologies' value of 0.17 is 96.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.29, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioStem Technologies's current Receivables Turnover of 0.17 is 96.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on BioStem Technologies and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioStem Technologies's current Receivables Turnover is 0.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioStem Technologies stock overvalued right now?
Based on GuruFocus' analysis, BioStem Technologies (BSEM) is currently considered Possible Value Trap. The stock's GF Value™ is $143.93, compared to a current price of $3.95 — trading 97.3% below its estimated fair value. The current Receivables Turnover is 0.17 and 96.8% below the Biotechnology industry median of 5.29. BioStem Technologies' overall GF Score™ is 49/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For BioStem Technologies (BSEM), the current Receivables Turnover is 0.17 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioStem Technologies (BSEM) Overvalued in 2026?
Based on GuruFocus' analysis, BioStem Technologies stock appears to be undervalued.
The current stock price of $3.95 is trading 97.3% below its estimated GF Value™ of $143.93.
GuruFocus considers BioStem Technologies to be Possible Value Trap.
Key valuation signals for BSEM:
Receivables Turnover: 0.17
GF Value™: $143.93 vs. price of $3.95 (97.3% below fair value)
Industry Position: 96.8% below the Biotechnology median (#557 of 841)
No single metric tells the full story. See the BSEM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioStem Technologies Inc is a regenerative biotechnology company focused on harnessing elements of perinatal tissue and the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. The company develops, manufactures, and sells tissue allografts for the wound care market with a focus on the treatment of diabetic, pressure, and venous ulcers. Utilizing its proprietary BioRetain processing method, it manufactures perinatal tissue allografts. The company offers a comprehensive portfolio of high-quality brands that are trademarked and include VENDAJE AC, AmnioWrap2, and Others. The company generates key revenue from VENDAJE AC.
49GF Score
Get the complete analysis for BSEM
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSEM has been successfully added to your 
